Individualized heparin monitoring and management reduces protamine requirements in cardiac surgery on minimal invasive extracorporeal circulation;A prospective randomized study

Abstract

Introduction

Individualized heparin and protamine management is increasingly used as a strategy to reduce coagulation activation and bleeding complications. While it is associated with increased heparin requirements during Cardiopulmonary Bypass (CPB), the impact on protamine administration remains controversial. We aim to investigate the effect of heparin level-guided monitoring on protamine dosing during cardiac surgery where low-anticoagulation protocols are implemented.

Methods

This is a prospective, randomized, controlled trial. A total of 132 patients undergoing elective full-spectrum cardiac surgery with Minimal Invasive Extracorporeal Circulation (MiECC) were recruited. All patients were managed by the same anaesthetic, surgical and perfusion team. Patients were randomly allocated in two groups; the individualized heparin-protamine titration (IHPT) group and the conventional heparinization and reversal group by using ACT (cACT) with a 0.75:1, protamine: heparin ratio. Titration was accomplished with the Hepcon HMS Plus (Medtronic, Minneapolis, MN) system. The primary outcome of the study was the total protamine dose used. Secondary outcomes comprised of the total heparin dose, the percentage of patients achieving target ACT, 24-h transfusion requirements, postoperative bleeding, duration of mechanical ventilation, major morbidity and length of hospital stay. Patients in each group were divided in two subgroups according to the target ACT; those operated for coronary artery bypass grafting (CABG) using a target ACT >300 s and the rest (non-CABG) patients operated with a target ACT >400 s, respectively.

Results

Protamine requirements were significantly reduced when IHPT was implemented; CABG (118 ± 24 mg vs 163 ± 61 mg; p < 0.001) and non-CABG cases (151 ± 46 mg vs 197 ± 45 mg; p < 0.001). Moreover, heparin requirements were significantly higher in the non-CABG subgroup managed with IHPT (34,539 ± 7658 IU vs 29,893 ± 9037 IU; p = 0.02). In overall, no significant differences were detected with respect to postoperative bleeding, transfusion of RBC or other blood products.

Conclusions

Individualized heparin monitoring and management reduces protamine requirements in cardiac surgery with MiECC implementing reduced anticoagulation strategy.

Trial registration

clinicaltrials.gov; NCT04215588.

Keywords

cardiac surgery coagulation heparin minimal invasive extracorporeal circulation point-of-care protamine

Get full access to this article

View all access options for this article.

References

Edmunds

. Cardiopulmonary bypass after 50 years. N Engl J Med 2004; 351: 1603–1606.

Sniecinski

Levy

. Anticoagulation management associated with extracorporeal circulation. Best Pract Res Clin Anaesthesiol 2015; 29: 189–202.

Wahba

Milojevic

Boer

, et al. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. Eur J Cardio Thorac Surg 2020; 57: 210–251.

Finley

Greenberg

. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg 2013; 116: 1210–1222.

Aziz

KAA

Masood

Hoschtitzky

, et al.

Does use of the Hepcon® point-of-care coagulation monitor to optimise heparin and protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery?

Interact Cardiovasc Thorac Surg 2006; 5: 469–482.

Radulovic

Laffin

Hansson

, et al. Heparin and protamine titration does not improve haemostasis after cardiac surgery: a prospective randomized study. PLoS One 2015; 10: e0130271.

Hoenicka

Rupp

Müller-Eising

, et al. Anticoagulation management during multivessel coronary artery bypass grafting: a randomized trial comparing individualized heparin management and conventional hemostasis management. J Thromb Haemostasis 2015; 13: 1196–1206.

Vonk

ABA

Veerhoek

van den Brom

, et al. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth 2014; 28: 235–241.

Nuttall

Smith

, et al. A blinded randomized trial comparing standard activated clotting time heparin management to high target active clotting time and individualized hepcon hms heparin management in cardiopulmonary bypass cardiac surgical patients. Ann Thorac Cardiovasc Surg 2022; 28: 204–213.

10.

Anastasiadis

Antonitsis

Murkin

, et al. MiECTiS focused update on the 2016 position paper for the use of minimal invasive extracorporeal circulation in cardiac surgery. Perfusion. 2022. DOI: 10.1177/02676591221119002.

11.

Anastasiadis

Murkin

Antonitsis

, et al. Use of minimal invasive extracorporeal circulation in cardiac surgery: principles, definitions and potential benefits. A position paper from the Minimal invasive Extra-Corporeal Technologies international Society (MiECTiS). Interact Cardiovasc Thorac Surg 2016; 22: 647–662.

12.

Bauer

Hausmann

Schaarschmidt

, et al.

Is 300 Seconds ACT Safe and Efficient during MiECC Procedures?

Thorac Cardiovasc Surg 2019; 67: 191–202.

13.

Pagano

Milojevic

Meesters

, et al. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. Eur J Cardio Thorac Surg 2018; 53: 79–111.

14.

Anastasiadis

Antonitsis

Argiriadou

, et al.

Modular minimally invasive extracorporeal circulation systems; can they become the standard practice for performing cardiac surgery?

Perfusion 2015; 30: 195–200.

15.

Raphael

Mazer

Subramani

, et al. Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. J Cardiothorac Vasc Anesth 2019; 33: 2887–2899.

16.

Mehta

Kellum

Shah

, et al. Acute kidney injury network: acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11(2): R31.

17.

Dyke

Aronson

Dietrich

, et al. Universal definition of perioperative bleeding in adult cardiac surgery. J Thorac Cardiovasc Surg 2014; 147: 1458–1463.

18.

Noui

Zogheib

Walczak

, et al. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device. Perfusion 2012; 27: 214–220.

19.

Argiriadou

Antonitsis

Gkiouliava

, et al. Minimal invasive extracorporeal circulation preserves platelet function after cardiac surgery: a prospective observational study. Perfusion 2020; 35: 138–144.

20.

Argiriadou

Antonitsis

Gkiouliava

, et al. Minimal invasive extracorporeal circulation preserves coagulation integrity. Perfusion 2022; 37: 257–265.

21.

Guffin

Dunbar

Kaplan

, et al. Successful use of a reduced dose of protamine after cardiopulmonary bypass. Anesth Analg 1976; 55: 110–113.

22.

Tanaka

Butt

Abuelkasem

, et al. protamine and coagulopathy after cardiopulmonary bypass: may the perfect electrostatic force be with you. J Cardiothorac Vasc Anesth 2023; 37: 1509–1510. DOI: 10.1053/j.jvca.2023.01.029.

23.

Boer

Meesters

Veerhoek

, et al. Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review. Br J Anaesth 2018; 120: 914–927.

24.

Abuelkasem

Mazzeffi

Henderson

, et al. Clinical impact of protamine titration-based heparin neutralization in patients undergoing coronary bypass grafting surgery. J Cardiothorac Vasc Anesth 2019; 33: 2153–2160.

25.

Koster

Börgermann

Gummert

, et al. Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: results of a randomized double-blind controlled pilot study. Clin Appl Thromb Hemost 2014; 20: 290–295.

26.

Wang

Zheng

. Blood loss after cardiopulmonary bypass, standard vs titrated protamine: a meta-analysis. Neth J Med 2013; 71: 123–127.

27.

Meesters

Veerhoek

de Jong

, et al. A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2016; 30: 1190–1195.

28.

Øvrum

Tangen

Tølløfsrud

, et al. Heparin-coated circuits and reduced systemic anticoagulation applied to 2500 consecutive first-time coronary artery bypass grafting procedures. Ann Thorac Surg 2003; 76: 1144–1148.

29.

Øvrum

Tangen

Tølløfsrud

, et al. Heparinized cardiopulmonary bypass circuits and low systemic anticoagulation: an analysis of nearly 6000 patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2011; 141: 1145–1149.

30.

O’Carroll-Kuehn

Meeran

. Management of coagulation during cardiopulmonary bypass. Cont Educ Anaesth Crit Care Pain 2007; 7: 195–198.

31.

Mulloy

Hogwood

Gray

, et al. Pharmacology of Heparin and Related Drugs. Pharmacol Rev 2016; 68(76): 76–141.

32.

Lemmer

Despotis

. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002; 123: 213–217.

33.

Bull

Korpman

Huse

, et al. Heparin therapy during extracorporeal circulation: I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975; 69: 674–684.

34.

Knapik

Cieśla

Przybylski

, et al. The influence of heparin resistance on postoperative complications in patients undergoing coronary surgery. Med Sci Mon Int Med J Exp Clin Res 2012; 18: CR105–CR111.

35.

Koster

Fischer

Praus

, et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002; 97: 837–841.

36.

Hofmann

Bushnaq

Kraus

, et al. Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid antifibrinolytic therapy. Perfusion 2013; 28: 412–418.

37.

Modrau

Halle

Nielsen

, et al. Impact of minimally invasive extracorporeal circulation on coagulation—a randomized trial. Eur J Cardio Thorac Surg 2020; 57: 1145–1153.